Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: A population-based cohort study
Main finding · OsteoarthritisResult — go to the resultHazard ratio 0.93 95% CI 0.83–1.05Authors' conclusion
The use of GLP-1RAs, primarily dulaglutide, was not associated with lower risk of osteoarthritis compared with DPP4Is use among patients with T2DM.
Study context
- Population
- Adults with T2D initiating GLP-1 RA or DPP-4i, National Health Insurance Service data of South Korea (2010–2022)nationwide cohort
- Exposure
- GLP-1 RA vs DPP-4i initiation
- Outcome
- Incident osteoarthritis
Methodological detailsnationwide, target trial emulation, propensity score fine stratification weighting
- Nationwide
- Target trial emulation
- Propensity score fine stratification weighting
Main finding
Osteoarthritis
Hazard ratio
0.93
95% CI 0.83–1.05
By group
GLP-1RAs
3.99 per 100 person-years
CI 3.54–4.48
DPP4Is
4.36 per 100 person-years
CI 4.34–4.38
GLP-1RAsvs DPP4Is
HR 0.93 (95% CI 0.83–1.05)
As reported in the abstract
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: A population-based cohort study. Diabetes Res Clin Pract. Published 7 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →